What's Happening?
Celltrion, a biopharmaceutical company, presented real-world evidence supporting the use of subcutaneous (SC) infliximab for patients with inflammatory bowel disease (IBD) at the UEG Week 2025 Meet the Expert sessions. The data demonstrated that switching from intravenous (IV) to SC infliximab is well tolerated and effective, with high treatment persistence and low relapse risk. The presentations included findings from the multicentric, prospective PEREM real-life cohort study, which showed that more than 95% of patients in remission remained on therapy after one year. The SC formulation of infliximab, known as CT-P13 SC, has been approved in 60 countries, including the US, and offers a convenient method of administration.
Why It's Important?
The introduction of subcutaneous infliximab provides a significant advancement in the treatment of IBD, offering patients a more convenient and potentially more effective option compared to traditional intravenous methods. This development could lead to improved patient adherence and outcomes, reducing healthcare costs associated with hospital visits for IV administration. The approval and positive real-world data of CT-P13 SC could influence treatment protocols and expand therapeutic options for IBD patients globally, impacting both healthcare providers and patients.
What's Next?
Celltrion's continued research and development in the field of biosimilars and novel therapeutics may lead to further innovations in treatment options for various diseases. The company may pursue additional approvals and expand the use of SC infliximab in other regions, potentially influencing global healthcare practices. Stakeholders, including healthcare providers and patients, will likely monitor the long-term efficacy and safety data to assess the broader impact of this treatment.
Beyond the Headlines
The shift from IV to SC infliximab highlights a broader trend in healthcare towards more patient-friendly treatment options that can be administered outside of traditional clinical settings. This could lead to increased patient autonomy and a shift in how chronic conditions are managed, with implications for healthcare delivery models and insurance coverage.
